SUPPLEMENTAL NOTES. Detailed clinical histories of selected patients with t-AML/t-MDS harboring
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vincristine, procarbazine, and prednisone) x 4 cycles followed by an autologous stem cell transplant with total body irradiation (1200 cGy), cyclophosphamide, and etoposide conditioning.
Four years after achieving complete remission, he relapsed with bone marrow involvement. He received EVAP (etoposide, vinblastine, doxorubicin, and prednisolone) x 7 cycles with a good response and clearance of his bone marrow. He relapsed again one year later. A bone marrow biopsy at this time showed a normal karyotype with no lymphoma involvement and no evidence of myelodysplasia. He received four cycles of nitrogen mustard, vincristine, and dexamethasone followed by four cycles of vincristine, cyclophosphamide, and dexamethasone. He also received radiation to his right iliopsoas region for loco-regional control. He was consolidated with an autologous stem cell transplant with BEAM (BCNU, etoposide, cytarabine, and melphalan)
conditioning. The leukapharesis sample used in this study was obtained at this time. Six years after his second autologous stem cell transplant, he presented with worsening fatigue, fever, anemia, thrombocytopenia, and leukocytosis. He was noted to have a peripheral blood blast count of 26%. A bone marrow biopsy was diagnostic for AML with a 40% blasts and complex cytogenetics including del5q and del7. Clonal biallelic mutations of TP53 were identified. He was induced with cytarabine and idarubicin. However, he went into septic shock and died on day+8 of induction chemotherapy. Approximately 3.5 years, later, he was diagnosed with MDS with del7. He underwent several rounds of treatment including azacytidine x 4 cycles, PXD-101 (a histone-deacetylase inhibitor)
x 8 cycles, and decitabine/arsenic x 3 cycles. His MDS was banked 2 years after its diagnosis.
He progressed to AML 3 years after his initial MDS diagnosis and died 3 months later.
